Literature DB >> 31862202

The immune checkpoints CTLA-4 and PD-L1 in carcinomas of the uterine cervix.

Georgia Karpathiou1, Celine Chauleur2, Mousa Mobarki3, Michel Peoc'h4.   

Abstract

BACKGROUND: Evasion of immune control is a major feature of malignant tumors. This tumor aspect is poorly studied in cervical lesions. AIM OF THE STUDY: To investigate the expression of PD-L1 and CTLA-4 in lesions of the uterine cervix.
MATERIAL AND METHODS: Sixty-three cervical lesions from 52 patients were immunohistochemically studied. The 63 lesions included 27 invasive adenocarcinomas, 19 squamous cell carcinomas (SCCs), 7 adenocarcinomas in situ, and 10 high-grade squamous intraepithelial lesions (CIN3).
RESULTS: CTLA-4 and PD-L1 tumor cell expression was found in 61.5 % and 26.9 % of the invasive cases, respectively. CTLA-4 tumor cell expression and PD-L1 tumor and immune cell expression were more often found in SCCs than in adenocarcinomas. CTLA-4 tumor cell expression was more often found in advanced FIGO tumors. PD-L1 and CTLA-4 immune cell expression was associated with lymph node metastasis. CTLA-4 expression did not affect survival. The prognosis was worse for PD-L1-expressing tumors.
CONCLUSION: CTLA-4 and PD-L1 are potential therapeutic targets in cervical cancer.
Copyright © 2019 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  Adenocarcinoma; Cervical; Dysplasia; Immunopathology; Immunotherapy; Lymphocytes; Prognosis

Mesh:

Substances:

Year:  2019        PMID: 31862202     DOI: 10.1016/j.prp.2019.152782

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  8 in total

1.  Overexpression of programmed cell death ligand 1 in patients with CIN and its correlation with human papillomavirus infection and CIN persistence.

Authors:  Ceyda Sancakli Usta; Eren Altun; Selim Afsar; Cagla Bahar Bulbul; Akin Usta; Ertan Adalı
Journal:  Infect Agent Cancer       Date:  2020-07-17       Impact factor: 2.965

2.  Endometrial Cancer Suppresses CD8+ T Cell-Mediated Cytotoxicity in Postmenopausal Women.

Authors:  Mickey V Patel; Zheng Shen; Marta Rodriguez-Garcia; Edward J Usherwood; Laura J Tafe; Charles R Wira
Journal:  Front Immunol       Date:  2021-04-23       Impact factor: 7.561

3.  Invasive Stratified Mucin-producing Carcinoma (ISMC) of the Uterine Cervix: Clinicopathological and Molecular Characteristics With Special Emphasis on the First Description of Consistent Programmed Death-ligand 1 (PD-L1) Over-expression.

Authors:  Sangjoon Choi; So-Woon Kim; Hyun-Soo Kim
Journal:  Cancer Genomics Proteomics       Date:  2021 Sep-Oct       Impact factor: 4.069

4.  A novel prognostic prediction model based on seven immune-related RNAs for predicting overall survival of patients in early cervical squamous cell carcinoma.

Authors:  Rui Qin; Lu Cao; Cong Ye; Junrong Wang; Ziqian Sun
Journal:  BMC Med Genomics       Date:  2021-02-15       Impact factor: 3.063

5.  The Prognostic Values of HPV Genotypes and Tumor PD-L1 Expression in Patients With HPV-associated Endocervical Adenocarcinoma.

Authors:  Feng Zhou; Hao Chen; Meiping Li; Amanda L Strickland; Wenxin Zheng; Xiaofei Zhang
Journal:  Am J Surg Pathol       Date:  2022-03-01       Impact factor: 6.394

6.  PD-L1, Mismatch Repair Protein, and NTRK Immunohistochemical Expression in Cervical Small Cell Neuroendocrine Carcinoma.

Authors:  Longyun Chen; Fan Yang; Ting Feng; Shafei Wu; Kaimi Li; Junyi Pang; Xiaohua Shi; Zhiyong Liang
Journal:  Front Oncol       Date:  2021-10-21       Impact factor: 6.244

7.  Programme death ligand 1 expressions as a surrogate for determining immunotherapy in cervical carcinoma patients.

Authors:  Sebastian A Omenai; Mustapha A Ajani; Clement A Okolo
Journal:  PLoS One       Date:  2022-02-09       Impact factor: 3.240

Review 8.  Emerging Therapeutic Strategies of Different Immunotherapy Approaches Combined with PD-1/PD-L1 Blockade in Cervical Cancer.

Authors:  Yanjun Ge; Yuchen Zhang; Kong-Nan Zhao; Haiyan Zhu
Journal:  Drug Des Devel Ther       Date:  2022-09-09       Impact factor: 4.319

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.